Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0005387
UniProt IDP05107
Primary gene name(s)ITGB2
Synonym gene name(s)CD18, MFI7
Protein nameIntegrin beta-2
Protein functionIntegrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrins alpha-M/beta-2 and alpha-X/beta-2 are receptors for the iC3b fragment of the third complement component and for fibrinogen. Integrin alpha-X/beta-2 recognizes the sequence G-P-R in fibrinogen alpha-chain. Integrin alpha-M/beta-2 recognizes P1 and P2 peptides of fibrinogen gamma chain. Integrin alpha-M/beta-2 is also a receptor for factor X. Integrin alpha-D/beta-2 is a receptor for ICAM3 and VCAM1. Contributes to natural killer cell cytotoxicity, PubMed:15356110. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils, PubMed:11812992. Triggers neutrophil transmigration during lung injury through PTK2B/PYK2-mediated activation, PubMed:18587400. Integrin alpha-L/beta-2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages, PubMed:23775590. {ECO:0000269|PubMed:11812992, ECO:0000269|PubMed:15356110, ECO:0000269|PubMed:18587400, ECO:0000269|PubMed:23775590}.
Subcellular locationMembrane;
Single-pass type I membrane protein.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P05107
Gene Ontology
(Biological Process)
Complete annatation
aging [GO:0007568];
apoptotic process [GO:0006915];
cell adhesion [GO:0007155];
cell-cell signaling [GO:0007267];
cell-matrix adhesion [GO:0007160];
cellular extravasation [GO:0045123];
cellular response to low-density lipoprotein particle stimulus [GO:0071404];
endodermal cell differentiation [GO:0035987];
endothelial cell migration [GO:0043542];
extracellular matrix organization [GO:0030198];
heterotypic cell-cell adhesion [GO:0034113];
inflammatory response [GO:0006954];
integrin-mediated signaling pathway [GO:0007229];
leukocyte cell-cell adhesion [GO:0007159];
leukocyte migration [GO:0050900];
leukocyte migration involved in inflammatory response [GO:0002523];
natural killer cell activation [GO:0030101];
neutrophil chemotaxis [GO:0030593];
phagocytosis [GO:0006909];
positive regulation of angiogenesis [GO:0045766];
positive regulation of NF-kappaB transcription factor activity [GO:0051092];
positive regulation of nitric oxide biosynthetic process [GO:0045429];
receptor clustering [GO:0043113];
receptor internalization [GO:0031623];
regulation of cell shape [GO:0008360];
regulation of immune response [GO:0050776];
regulation of peptidyl-tyrosine phosphorylation [GO:0050730];
toll-like receptor 4 signaling pathway [GO:0034142]
Gene Ontology
(Molecular Function)
Complete annatation
cell adhesion molecule binding [GO:0050839];
glycoprotein binding [GO:0001948];
ICAM-3 receptor activity [GO:0030369];
metal ion binding [GO:0046872];
protein kinase binding [GO:0019901]
Gene Ontology
(Cellular Component)
Complete annatation
cell surface [GO:0009986];
extracellular exosome [GO:0070062];
extracellular vesicle [GO:1903561];
integrin alphaL-beta2 complex [GO:0034687];
integrin complex [GO:0008305];
membrane [GO:0016020];
plasma membrane [GO:0005886];
receptor complex [GO:0043235];
secretory granule [GO:0030141]
Protein-protein interaction109895
Phylogenetic treeP05107
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-1.574113839269752.58457684354507e-061.83144062933293e-05
AZA vs. DISU-0.8178617182176820.001282697695453530.0907764556866971
AZA vs. IL7-0.07317942391512790.7028660148380990.999311006273513
AZA vs. SAHA-0.776427861738740.001564509014198580.0279958009253755
DISU vs. CD30.745887091985490.0406101299374780.091325838979195
DISU vs. IL70.7348843991829930.004265108963271590.0677518626146673
DISU vs. SAHA0.04375407062914560.8809276207701610.96945856056033
DMSO vs. AZA0.04869373838044840.7704372900831731
DMSO vs. CD31.611125800960138.98752242073364e-076.52830401486752e-06
DMSO vs. DISU0.8646303868733270.0004229352161192470.0398352106682316
DMSO vs. IL7-0.1144494874890720.5229834970242080.892062483435342
DMSO vs. SAHA-0.830078206070830.0004595452632731870.0102452761283879
HIV vs. Mock in Activation0.1759918362580730.7771395474998810.999983755607037
HIV vs. Mock in Latency0.02565763245050070.8761830871041770.999834320637052
IL7 vs. CD31.50651871725914.70094202020821e-063.92343848674409e-05
SAHA vs. CD30.7751864165081520.0300174362554120.0648734783262668
SAHA vs. IL7-0.7053282753263510.00386561691560250.0320027068539294
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.569985 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.956 1.008 1.173 1.171 1.219
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00641 Simvastatin approved unknown other

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1JX3 Model - A=126-364.
1L3Y NMR - A=535-574.
1YUK X-ray 1.8Å A=23-125# B=365-482.
2JF1 X-ray 2.2Å T=735-769.
2P26 X-ray 1.7Å A=23-535.
2P28 X-ray 2.2Å A=23-122# B=362-574.
2V7D X-ray 2.5Å P/Q/R/S=755-764.
3K6S X-ray 3.5Å B/D/F/H=23-699.
3K71 X-ray 3.9Å B/D/F/H=23-699.
3K72 X-ray 3.7Å B/D=23-699.
4NEH X-ray 2.7Å B=23-695.
4NEN X-ray 2.9Å B=23-696.
5E6R X-ray 2.9Å B=23-482.
5E6S X-ray 2.1Å B/D/F=23-482.
5E6U X-ray 2.5Å B=23-482.
5E6V X-ray 1.8Å A=24-482.
5E6W X-ray 2.2Å A=23-118# A=362-574.
5E6X X-ray 1.7Å A=23-535.
5ES4 X-ray 3.3Å B/D/F/H=23-696.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Tat inhibits 11751951
Envelope surface glycoprotein gp160; precursor interacts with 22190034
Envelope surface glycoprotein gp120 interacts with 1967280
1972106922190034
8558011
22908191
matrix co-localizes with 22017400
Tat cooperates with 20661303
Vpr upregulates 23874603
Tat upregulates 8568270
Tat interacts with 8757599

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04015 Rap1 signaling pathway - Homo sapiens (human)
hsa04145 Phagosome - Homo sapiens (human)
hsa04390 Hippo signaling pathway - Homo sapiens (human)
hsa04514 Cell adhesion molecules (CAMs) - Homo sapiens (human)
hsa04610 Complement and coagulation cascades - Homo sapiens (human)
hsa04650 Natural killer cell mediated cytotoxicity - Homo sapiens (human)
hsa04670 Leukocyte transendothelial migration - Homo sapiens (human)
hsa04810 Regulation of actin cytoskeleton - Homo sapiens (human)
hsa05133 Pertussis - Homo sapiens (human)
hsa05134 Legionellosis - Homo sapiens (human)
hsa05140 Leishmaniasis - Homo sapiens (human)
hsa05144 Malaria - Homo sapiens (human)
hsa05146 Amoebiasis - Homo sapiens (human)
hsa05150 Staphylococcus aureus infection - Homo sapiens (human)
hsa05152 Tuberculosis - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)
hsa05323 Rheumatoid arthritis - Homo sapiens (human)
hsa05416 Viral myocarditis - Homo sapiens (human)
Menu